Crosstalk between the insulin-like growth factors and estrogens in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 5, Issue 1, 2000, Pages 107-115

  Yee, D ^a   Lee, A V ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Insulin like growth factors; Signal transduction

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; SOMATOMEDIN;

BREAST CANCER; CELL PROLIFERATION; EXPERIMENTAL MODEL; GENETIC REGULATION; GROWTH STIMULATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; INHIBITION KINETICS; MITOGENESIS; MOLECULAR INTERACTION; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 0033842834     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009575518338     Document Type: Review

References (81)

1. Estrogen receptor as a target for the prevention of breast cancer
2. The nuclear receptor superfamily: The second decade
3. Cloning of a novel receptor expressed in rat prostate and ovary
4. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta
5. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
6. Transcriptional activation by oestrogen receptors
7. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
8. Dopaminergic and ligand-independent activation of steroid hormone receptors
9. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor
10. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol
11. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element
12. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells - A comparison of the effects of cyclic adenosine 3',5'-monophosphate, estradiol, insulin-like growth factor-I, and serum factors
13. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen
14. Estrogen receptors: Bioactivities and interactions with cell signaling pathways
15. Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells
16. Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells
17. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
18. Enhancement of the insulin-like growth factor pathway by estrogen in human breast cancer cells
19. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells
20. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells
21. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
22. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activity
23. Two separate mechanisms for ligand-independent activation of the estrogen receptor
24. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor
25. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region
26. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity
27. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
28. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
29. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I
30. Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells
31. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta
32. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
33. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3
34. Ras mediates the insulin-dependent activation of the unliganded estrogen receptor in human neuroblastoma cells
35. CDK-independent activation of estrogen receptor by cyclin D1
36. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4
37. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
38. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor
39. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
40. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth-hormone-induced IGF-I messenger ribonucleic acid
41. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus
42. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol
43. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen
44. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen
45. Effects of antioestrogens on the proliferation of MCF-7 human breast cancercells
46. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
47. Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
48. Insulin-like growth factor II mRNA expression in human breast cancer
49. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes
50. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action
51. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
52. Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1 (m/m) mouse
53. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation
54. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
55. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention
56. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
57. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor-binding protein 3 autocrine loop in human breast cancer cells
58. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status
59. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activity
60. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells
61. Autocrine production of insulin like growth factor-II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells
62. Insulin-like growth factor-II over expression in MCF-7 cells induces phenotypic chances associated with malignant progression
63. Tamoxifen resistant MCF-7 cells exhibit increased expression of insulin-like growth factor-II
64. Type IIGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells
65. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells
66. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol
67. Overexpression of IRS-1 in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation
68. Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro
69. Status of the insulin-like growth factor network in an estrogen receptor negative T47D breast cancer cell clone
70. Loss of estrogen receptor in MCF-7 breast cancer cells is associated with reduced IGFR1 and IRS-1 expression, diminished IGF signaling, and a failure to respond mitogenically to IGFs
71. Influence of estrogens on mouse uterine epidermal growth factor precursor protein and messenger ribonucleic acid
72. Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells
73. Estrogen induces insulin-like growth factor-I expression in the rat uterus
74. Uterine insulin-like growth factor-I receptors: Regulation by estrogen and variation throughout the estrous cycle
75. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation
76. Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor
77. Impaired estrogen action in the uterus of insulin-like growth factor binding protein-1 transgenic mice
78. Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts
79. Polyetheylene glycol conjugated insulin-like growth factor binding protein inhibits growth of breast cancer in athymic mice
80. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells